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Evidence garnered from genetic,(Hollingworth et al., 2007; Sweet et al., 2010; Sweet et al.,
2002) longitudinal (below), and imaging (below) studies of Alzheimer’s disease (AD)
complicated by a psychotic course (AD+P) support its syndromal distinction from its nonpsychotic counterpart (AD−P); very recent work on the neurobiology of the disorder point
towards frontal systems deficits and an overrepresentation of one of the pathological protein
hallmarks of the disease as potentially etiologically related to the development of psychosis.
The identification of a specific neuropathological etiology of psychosis could pave the way
to new treatment approaches for a condition that currently relies on the use of antipsychotic
medication that have been reported to contribute to an exacerbation of cognitive impairment,
(Schneider et al., 2006; Vigen et al., 2011) and that carry a ‘black box warning’ for use in
the elderly with AD. (FDA, 2005)
Converging evidence suggests that AD+P may represent a relative acceleration of frontal
pathology, with tau pathology playing a primary role. AD+P can be distinguished from AD
−P in its association with a greater burden of cognitive impairment and a more rapid
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cognitive decline, as concluded by a review of 55 studies of AD+P. (Ropacki and Jeste,
2005) This association has subsequently been confirmed in more recent studies (Sweet et al.,
2010; Sweet et al., 2012; Wilkosz et al., 2010); the decline has consistently been found to
predate the onset of psychosis, suggesting a pathological process that finds expression in
both deterioration and psychosis. (Emanuel et al., 2011; Paulsen et al., 2000; Weamer et al.,
2009) The contribution of neurodegenerative pathology to the psychotic course of AD is
suggested by a hastened mortality. (Lopez et al., 2013; Scarmeas et al., 2005; Wilson et al.,
2005) The constellation of aggravated cognitive deficits in AD+P suggests disruption of
frontal systems (Jeste et al., 1992; Paulsen et al., 2000) with working memory tasks
particularly affected. (Koppel et al., 2012; Koppel et al., 2013c; Murray et al., 2013a)
Computer-assisted tomography; magnetic resonance imaging; single-photon emission
computed tomography; and [18F]-Fluorodexyglucose Positron Emission Tomography
studies of AD+P also consistently but not exclusively implicate frontal systems. (Murray et
al., 2013b)
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A number of reports suggest that tau may be a unique contributor to the putative
neurodegenerative process in AD+P. Neurofibrillary tangles (NFTs) are one of the
pathological hallmarks of AD whose distribution correlates with severity of disease.
(Arriagada et al., 1992) Tau is abnormally phosphorylated in AD, a critical event leading to
abnormal folding and cleavage with aggregation of the protein and the eventual
development of NFT pathology. (Goedert, 1993; Mondragon-Rodriguez et al., 2008) Tau is
hyperphosphorylated in AD at 19 specific amino acid sequences, with evidence indicating
that phosphorylation at particular sites correlate with the maturity of pathology and that
individual sites may be critical for conformational changes from pre-tangles leading to
neuronal tangles to eventual extracellular tangles. (Augustinack et al., 2002; Kimura et al.,
1996) Previous studies have reported an increased burden of NFT pathology in frontal
cortex in AD+P, although these studies have relied on semi-quantitative transformation of
histochemical detection of fibrillar tau. (Farber et al., 2000; Zubenko et al., 1991) A recent
neuropathological correlation study of prefrontal cortical sections from a post-mortem AD
+P sample used quantitative fluorescence microsopy and observed an increased burden of
intraneuronal tau phosphorylated at Ser199/Ser202/Thr205. (Murray et al., 2013a) In a study
conducted on a data sample drawn from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI), cerebrospinal fluid (CSF) biomarkers of AD (total tau, Thr181 phospho-tau, and
Aβ) were explored as predictors of the development of psychosis. Elevation of total tau was
associated with the future development of AD+P. (Koppel et al., 2013a) An association of
CSF total and Thr181 phospho-tau with gender was also reported; when the genders were
separated, females- but not males-with subsequent development of AD+P manifested
baseline elevations of Thr181 phosho-tau and total tau.
No previous studies have used a biochemical approach to precisely quantify concentrations
of pathogenic tau in brains of those with AD+P, or explored whether particular tau
phosphorylation sites predominate in AD+P that could distinguish it from AD−P. In order to
quantify tau abnormalities in the frontal cortex in AD+P across a range of phosphorylation
sites, and to explore the impact of gender on those abnormalities, we employed a sensitive
biochemical assay of 4 epitopes of phospho-tau (Ser396/404; Ser202;Thr231; Ser199/202/
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Thr205) utilizing monoclonal antibodies known to recognize a wide range of tau pathology
in a post-mortem sample of AD+P and AD−P.
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Materials and Methods
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All subjects (Table 1) underwent neurologic, neuropsychologic, and psychiatric diagnostic
evaluations as part of their participation in the Clinical Core of the Alzheimer Disease
Research Center (ADRC) at the University of Pittsburgh. (Murray et al.; Sweet et al., 2001;
Sweet et al., 2000) Psychiatrists with specialized training in geriatric psychiatry conducted
semi-structured examinations, and the patient, primary caregiver, and all other available
informants were interviewed. As part of the semi-structured examinations, the presence or
absence of hallucinations and delusions was determined and rated on the Consortium to
Establish a Registry for Alzheimer’s disease (CERAD) Behavioral Rating Scale. (Tariot et
al., 1995) Hallucinations were defined as sensory perceptions with no basis in reality.
Delusions were defined as a false belief based on incorrect inference about reality and not
attributable to membership in a social or cultural group. Psychosis was the presence of
hallucinations or delusions at any visit. Subjects with psychosis occurring solely during an
episode of delirium were not rated as AD+P. No patient had a history of schizophrenia,
schizoaffective disorder, or other idiopathic psychosis. Years of death ranged between 2000
to 2011.
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A neuropathologic diagnosis of AD was made at postmortem examination. (Mirra et al.,
1991) At the time of brain removal, the post mortem interval in hours was recorded, and the
brain was removed intact, examined grossly, and divided in the midsagittal plane. Gray
matter samples from the right superior frontal gyrus were dissected and frozen at −80 °C.
The left hemibrain was immersion fixed in 10% buffered formalin for at least one week,
sectioned into 1.0–2.0 cm coronal slabs, and sampled according to CERAD protocol for
neuropathological diagnosis. (Mirra et al., 1991) Samples from the midfrontal cortex,
cingulate gyrus and caudate nucleus, hippocampus at the level of the lateral geniculate
nucleus, inferior parietal lobule, superior and middle temporal cortex, primary visual cortex,
amygdala, and transentorhinal cortex were stained using the Bielschowsky technique
according to the Yamamoto and Hirano modification. (Yamamoto and Hirano, 1986)
Samples from amygdala, midbrain, pons and medulla were immunostained for ubiquitin and
α-synuclein, and Lewy body pathology was rated. (McKeith et al., 1996) If any of these
sections were positive, sections from cortex, hippocampus, and remaining brainstem were
also stained for α-synuclein. Neuritic plaques were semiquantiatively scored according to
CERAD criteria;(Mirra et al., 1991) plaque density per 100x microscopy field was rated as
“none,” “sparse,” “moderate,” or “frequent,” with most subjects scored as “frequent”. Braak
staging was done on Bielschowsky stained sections of mesial temporal lobe (hippocampus
with entorhinal, transentorhinal and inferior temporal lobe cortex), mid-frontal, inferior
parietal, superior temporal gyri and occipital lobe containing the primary visual cortex and
adjacent cortex. (Braak and Braak, 1991)
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Previous studies have suggested that accelerated frontal neurodegeneration may be a feature
of the pathogenic process in psychotic AD. (Koppel et al., 2013c; Murray et al., 2013a) For
this reason, the current study focused on frontal cortex. Brain samples of superior frontal
gyrus drawn from 26 AD−P subjects and 45 AD+P subjects. There were 35 males and 36
females included in the study. AD+P and AD−P groups were well balanced for gender, age
at death, and post-mortem Braak staging (Table 1). The Braak staging system (I–VI) is
based on the gradual appearance of neurofibrillary tangle pathology in a hierarchical pattern
beginning in the perirhinal cortex (Stage I) in preclinical disease and eventually appearing to
all areas of association cortex in severe disease (Stage VI). (Braak and Braak, 1995) The
approximate equivalence of Braak stage between AD+P and AD−P sample groups assures
that the groups are well matched for global neuropathological severity and allows for an
exploration of the regional specificity of tau protein pathology in AD+P.

NIH-PA Author Manuscript

In order to quantify levels of tau in the cortex across a broad spectrum of phospho-tau
epitopes implicated in AD, a series of sandwich ELISAs employing monoclonal antibodies
were performed in the AD+P and AD−P groups. A level of total tau was measured with
DA31; Ser396/404 phospho-tau known to be well represented in early and late Braak stages
and present in a spectrum from early to mature tau aggregates (Mondragon-Rodriguez et al.,
2013) was quantified with PHF-1; Ser202 phospho-tau was quantified with CP13, an
antibody that detects early neuritic pathology(Janocko et al., 2012); Thr231phospho-tau, a
conformational epitope often phosphorylated even in pre-tangles (Augustinack et al., 2002)
was quantified with RZ3; and Ser199/202/Thr205 phospho-tau, represented in more severe
cases, (Augustinack et al., 2002) was quantified with AT8.
Preparation of brain samples and ELISA were performed according to previously published
methods. (Acker et al., 2013)
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Briefly, the brain regions were extracted and homogenized in a 10x volume of
homogenizing buffer, a solution of Tris-buffered saline (TBS), pH 7.4 containing 10mM
NaF, 1mM NaVO3, and 2mM EGTA, including a complete Mini protease inhibitor (Roche).
Samples were stored in aliquots at −80°C until use. Prior to use, homogenates were thawed
and spun at 14,000 g for 10 min at 4°C. Brain homogenate samples were diluted in 20%
SuperBlock in 1X TBS (ThermoScientific) and processed as previously described. (Acker et
al., 2013)
Quantification of tau levels were analyzed by sandwich ELISA measurements. DA31
(aa150–190), PHF1 (pSer396/404), CP13 (pSer202), and RZ3 (pThr231) and AT8 (pSer199/
p202/pThr205) at a concentration of 6 μg/ml were used as the capture antibody for four
separate ELISA measurements. DA9-HRP (aa102–140) at a concentration of 0.3 μg/ml was
used as the detection antibody for all assays. Tau sandwich ELISA was performed as already
published 96-well plates were respectively coated with DA31, CP13 at a final concentration
of 6 mg/ml in coating buffer, for at least 48 h at 4uC. After washing 3X in wash buffer, the
plates were blocked for 1 h at room temperature using StartingBlock (Thermoscientific) to
avoid non-specific binding. Each plate was then washed 5X and 50 ml of the appropriate
sample was added to the wells. Concurrently, 50 ml of DA9-HRP detection antibody was
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added to the samples and tapped to combine. Plates were incubated O/N shaking at 4uC and
then washed 9X in wash buffer. 1-Step ULTRA TMB-ELISA (Thermoscientific) was added
for 30 minutes at room temperature before stopping the reaction with 2 M H2SO4. Plates
were read with an Infinite m200 plate reader (Tecan) at 450 nm
Statistics
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The current study was designed around a convenience sample of well characterized premortem and post-mortem pathology in subjects with AD+P and AD−P with available frontal
cortical tissue for tau analysis. As such, a power analysis for sample size calculation was not
conducted. Parametric (two-way ANOVA, Student t) and non-parametric (Chi-squared) tests
of demographic independent and dependent outcome variables were employed, with an
alpha risk set at 0.05. As total tau was not anticipated to differ between groups, while
phospho-tau species were expected to differ, these analyses were separated. Differences in
levels of total tau (DA31) between AD+P and AD−P groups were compared with a
Student’s t-test. For levels of phosphotau, the entire panel of epitopes (PHF-1; CP13; RZ3;
AT8) in AD+P and AD−P were first compared with a two-way ANOVA to evaluate
differences between the groups, followed by individual two-tailed Student’s t-test within
each epitope.

Results

NIH-PA Author Manuscript

In the total sample, levels of phospho-tau did not differ between psychotic (AD+P) and nonpsychotic (AD−P) groups (Figure 1.) A post-hoc analysis of evidence from a previously
published report of CSF biomarkers in AD+P suggest that while total tau and Thr181
phosphotau are elevated in females with AD+P, males with AD+P may not manifest these
differences. (Koppel et al., 2013b) For this reason, we divided our sample by gender. This
analysis included 13 AD−P and 23 AD+P female subjects; 13 AD−P and 22 AD+P male
subjects. Both gender groups were well balanced for age at death, with Braak staging
reflecting slightly more extensive tangle pathology in females with AD+P, and slightly less
tangle pathology in males with AD+P (Table 1). In females, levels of non-pathogenic total
tau tau did not differ between AD+P and AD−P groups. However, pathogenic phospho-tau
species did differ significantly between groups (F [1,136] = 20.56, p<0.0001). AD+P
females had significantly higher levels of phosphorylated tau than AD−P females at every
epitope interrogated: Ser396/404; Ser202; Thr231; and Ser199/202/Thr205 (Figure 2). This
suggests a broad range of pre-tangle, neuritic, and mature tangle pathology in the frontal
cortex of AD+P female. In males, as in females, levels of non-pathogenic total tau did not
differ between groups. Levels of pathogenic phospho-tau species did differ between groups,
although in an opposite direction from females (F [1,132] =14.94, p=0.0002). Unexpectedly,
levels of Thr231 and Ser199/202/Thr205 were statistically significantly higher in AD−P
males when compared with AD+P males, an trend of inversion of what was observed in
females; levels of Ser202 and Ser396/404 followed the same trend, but were not statistically
significantly different (Figure 3).
The gender-specific inversion of risk modification was not predicted. In order to explore
what was driving psychosis in males, the impact of α-synuclein pathology on psychosis risk
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was explored in males and females. Psychosis-canonically expressed in visual hallucinations
but often including delusions- is a core diagnostic feature of dementia with Lewy bodies
(DLB), a disease of α-synuclein pathology. (McKeith, 2006) In fact, the early presence of
psychosis is more predictive of DLB than either of its other core features: parkinsonism or
fluctuating cognition. (Tiraboschi et al., 2006) In order to explore the contribution of αsynuclein pathology to gender stratified psychosis risk, the sample was divided into a group
with and without Lewy body pathology anywhere in the brain at post-mortem examination.
36 subjects had Lewy body pathology and 35 subjects did not. In females, 14/23 AD+P
subjects had Lewy body pathology, compared with 6/13 AD−P subjects (Χ2=0.7, p=0.4). In
males, 13/22 AD=P subjects had Lewy body pathology, compared with only 3/13 AD−P
subjects (Χ2=4.3=, p=0.04). This suggests that while tau pathology is the critical molecular
modifier of psychosis risk in females with AD, α-synuclein may play an analogous role in
males.

Discussion

NIH-PA Author Manuscript

The identification of accelerated decline and early mortality in AD+P necessitates an
explication of the mechanism responsible for the divergent path this syndrome takes. From
the standpoint of brain topography, it seems clear from imaging studies that the frontal
cortex plays a unique role in AD+P. However, the molecular biology of the frontal
pathogenic process has yet to be elucidated. The starting point for any such exploration
should begin with the known histological hallmarks of AD, amyloid-beta (Aβ) and tau
protein pathology. Indeed, previous studies have explored both pathologies. While results of
investigations correlating regional Aβ plaque deposition with AD+P have been largely
negative, similar approaches focused on tau pathology have been generally positive.
(Murray et al., 2013b) The first study to explore neuropathological relationships with
psychosis in AD demonstrated increased neurofibrillary tangle pathology in the middle
frontal cortex of subjects with AD+P. (Zubenko et al., 1991) Two subsequent studies of
similar design were split in reporting an increased burden of tangle pathology in AD+P.
(Farber et al., 2000; Sweet et al., 2000) Taken together, the preponderance of evidence from
semi-quantitative tangle burden association studies does suggest a risk relationship between
tau pathology and psychosis in AD.

NIH-PA Author Manuscript

Results of the current quantitative tau pathology report suggest that while alterations in tau
pathology are a feature of AD+P, those alterations are gender-specific. Previous
neuropathology studies have not divided samples by gender. However, female gender has
been reported in several studies to be an independent risk factor for psychosis in AD.
(Hirono et al., 1998; Leroi et al., 2003; Rockwell et al., 1994; Schneider and Dagerman,
2004) Recent imaging studies have explored the biologic correlates of gender-based
psychosis risk in AD, and implicate frontal involvement in women only. A magnetic
resonance imaging study in AD+P demonstrated reduced frontotemporal cortical thickness
in women, but not men, with AD+P. (Whitehead et al., 2012) A voxel-based analysis of
whole brain cerebral perfusion was undertaken in a large sample of AD+P (N=51) and AD
−P (N=52) subjects. (Moran et al., 2008) In this study, perfusion patterns were vastly
different between AD+P females and AD+P males. In female AD+P subjects, there was a
marked hypoperfusion in right infero-lateral prefrontal cortex and right inferior temporal
Neurobiol Aging. Author manuscript; available in PMC 2015 September 01.
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region compared with controls. In males, AD+P correlated with an increased perfusion in
the right striatum compared with controls. Of note, these deficits were non-overlapping and
represent what the authors describe as a “double dissociation of gender and cerebral
function,” and suggest that localized pathology contributing to behavioral abnormalities may
have gender specificity. (Moran et al., 2008)
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The results of this report proved further evidence of a potential “double dissociation” of
gender and pathophysiology in AD+P. In the current sample, females with AD+P had an
increased burden of phosphotau evident in the superior frontal gyrus at all four epitopes
interrogated compared with female AD−P subjects. Inversely, males with AD+P did not
have of evidence of this burden, and appear to have a relative deficit of phosphotau. The
results from the females are consistent with the concatenation of evidence pointing to a
frontal deficit in AD+P. This may represent a focal frontal-superimposed on a necessary but
cortically diffuse-neurodegenerative process. The elevation of concentrations of phospho-tau
across a broad range of epitopes, together with the lack of specificity of tau kinases for any
particular epitope (Augustinack et al., 2002) preclude a search for a responsible kinase.
Whether accelerated tangle pathology is the pathogenic driver of psychosis in AD females,
with a concomitant but accidental impact on frontal brain function, or whether frontal
impairment is pathogenic, with tangle pathology as a convenient source, is an important
question.
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In the males, while a lack of hyper-phosphorylation in AD+P could be understood as an
issue of regional, gender-based specificity in a study that only looked at one region, the
inversion of the risk relationship with tau requires elucidation. Males with AD+P were more
likely to have α-synuclein pathology, while females were not. This suggests that while tau
driven neurodegeneration of frontal cortex may be a risk factor for psychosis in females, αsynuclein pathology, known to be associated with psychosis in DLB, may be risk factor in
males. The relative deficit of phosphotau in the superior fontal gyrus males with AD+P
suggests that preservation of integrity in this region is a risk factor for psychosis. In a
previous study correlating delusional severity with regional brain metabolism in a sample of
24 men and 1 woman, increased metabolism in the right lateral orbitofrontal region
(Brodmann’s area 47) was associated with a greater severity of delusions, while other
regional associations with delusional severity were in the direction of deficient metabolism.
(Sultzer et al., 2003) If true, this would suggest that tangle pathology itself is not the
causative agent in psychotic AD, but that the complex relationship of frontal systems with
other brain regions, altered in AD, may be the critical mediator of the emergence of
psychosis.
In synthesizing the available data, we suggest a new model for exploring the neurobiology
of AD+P. In this model, regional networks of altered brain functions that include areas of
relative deficit and preservation driven by the topography of pathology- whether tau or αsynuclein- may be responsible for psychosis in AD; these may be gender-specific risk
patterns. If so, future research in psychotic AD exploring the impact of regional brain
dysfunction and its potential gender-specific correlation with tau or α-synuclein pathology
would be of particular interest. The recently reported positive developments in tau imaging
technology in PET scanning (Chien et al., 2014) may afford the opportunity for those studies
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to move forward. This model may also help to guide future studies seeking to identify
genetic variants responsible for AD+P; indeed, the heritability of AD+P has been estimated
at 61%,(Sweet et al., 2010) yet despite identifying a number of candidate genes, a metaanalysis of three combined genome-wide association datasets including over 7,500 subjects
did not ascertain any genetic polymorphisms that achieved threshold statistical significance.
(Hollingworth et al., 2012) One potential explanation for this may involve genderdifferentiated effects that have not been explored in these datasets, in which the magnitude
or even direction of genetic effect could differ based on gender. (Magi et al., 2010) Future
analyses employing male-specific, female-specific, or gender-differentiated approaches
(Magi et al., 2010) may help to bridge the gap between heritability estimates and gene
identification.
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Figure 1.

Mean levels of total tau (a.) and hyperphosphorylated tau: PHF1 (pSer396/404), CP13
(pSer202), RZ3 (pThr231) and AT8 (pSer199/p202/pThr205) (b.–e.) in superior frontal gyri
of subjects with AD without psychosis (AD−P, N=26) compared with AD and psychosis
(AD+P, N=45), 95% confidence intervals are represented.
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Figure 2.

Mean levels of total tau (a.) and hyperphosphorylated tau: PHF1 (pSer396/404), CP13
(pSer202), RZ3 (pThr231) and AT8 (pSer199/p202/pThr205) (b.–e.) in superior frontal gyri
of females without psychosis (AD−P, N=13) compared with AD and psychosis (AD+P,
N=23). 95% confidence intervals are represented and significant individual differences
(p<0.05) are highlighted.
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Figure 3.

Mean levels of total tau (a.) and hyperphosphorylated tau: PHF1 (pSer396/404), CP13
(pSer202), RZ3 (pThr231) and AT8 (pSer199/p202/pThr205 (b.–e.) in superior frontal gyri
of males with AD without psychosis (AD−P, N=13) compared with AD and psychosis (AD
+P, N=22). 95% confidence intervals are represented and significant individual differences
(p<0.05) are highlighted.
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Demographics of AD subjects with psychosis (AD+P, N=45) and without psychosis (AD−P, N=26). Means
(standard deviation) shown.
Total Sample
AD + P

AD − P

Male

22

13

Female

23

13

Age

82.9 (1.0)

83.4 (1.8)

Braak

4.9 (0.1)

4.9 (0.2)

Age

83.5 (1.3)

87 (2.4)

Braak

5.1 (0.1)

4.6 (0.3)

Age

82.2 (0.7)

79.9 (2.4)

Braak

4.7 (0.2)

5.1 (0.2)

Females

Males
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